Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization

Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization

Ahmad M Mansour,1,2 Friederike Mackensen,3 Padmamalini Mahendradas,4 Moncef Khairallah,5 Timothy YY Lai,6 Ziad Bashshur11Department of Ophthalmology, American University of Beirut, 2Rafic Hariri University Hospital, Beirut, Lebanon; 3Interdisciplinary Uveitis Center, University of Heidelberg, Heidel...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Mansour AM, Mackensen F, Mahendradas P, Khairallah M, Lai TY, Bashshur Z
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/ea3ccae7544743858a37bcaf60f0399d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ea3ccae7544743858a37bcaf60f0399d
record_format dspace
spelling oai:doaj.org-article:ea3ccae7544743858a37bcaf60f0399d2021-12-02T08:47:32ZFive-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization1177-54671177-5483https://doaj.org/article/ea3ccae7544743858a37bcaf60f0399d2012-08-01T00:00:00Zhttp://www.dovepress.com/five-year-visual-results-of-intravitreal-bevacizumab-in-refractory-inf-a10587https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Ahmad M Mansour,1,2 Friederike Mackensen,3 Padmamalini Mahendradas,4 Moncef Khairallah,5 Timothy YY Lai,6 Ziad Bashshur11Department of Ophthalmology, American University of Beirut, 2Rafic Hariri University Hospital, Beirut, Lebanon; 3Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; 4Departments of Uveitis and Retina, Narayana Nethralaya, Bangalore, India; 5Department of Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia; 6Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong KongPurpose: To assess the 5-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization.Methods: Retrospective, multicenter, consecutive case series of eight patients with inflammatory ocular neovascularization refractory to standard therapy who were treated with intravitreal bevacizumab and followed for 5 years after first injection. The outcome measures included improvement of best-corrected visual acuity expressed as logarithm of minimum angle of resolution.Results: Mean best-corrected visual acuity significantly improved from 0.58 at baseline (6/23 or 20/76; standard deviation = 0.32) to 0.20 at final assessment (6/10 or 20/32; standard deviation = 0.25) (n = 8; P = 0.02), a gain of 3.8 lines (median: three injections; eight eyes; eight patients). No ocular or systemic complications from intravitreal bevacizumab were noted.Conclusion: At 5 years, intravitreal bevacizumab sustained significant visual improvement in ocular neovascularization due to a variety of inflammatory ocular diseases without major complications after a median of three injections.Keywords: bevacizumab, choroidal neovascularization, punctate inner choroidopathy, toxoplasmosis, uveitis, Vogt–Koyanagi–Harada syndromeMansour AMMackensen FMahendradas PKhairallah MLai TYBashshur ZDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 1233-1237 (2012)
institution DOAJ
collection DOAJ
language EN
topic Ophthalmology
RE1-994
spellingShingle Ophthalmology
RE1-994
Mansour AM
Mackensen F
Mahendradas P
Khairallah M
Lai TY
Bashshur Z
Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
description Ahmad M Mansour,1,2 Friederike Mackensen,3 Padmamalini Mahendradas,4 Moncef Khairallah,5 Timothy YY Lai,6 Ziad Bashshur11Department of Ophthalmology, American University of Beirut, 2Rafic Hariri University Hospital, Beirut, Lebanon; 3Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany; 4Departments of Uveitis and Retina, Narayana Nethralaya, Bangalore, India; 5Department of Ophthalmology, Fattouma Bourguiba University Hospital, Monastir, Tunisia; 6Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong KongPurpose: To assess the 5-year visual outcome of intravitreal bevacizumab in inflammatory ocular neovascularization.Methods: Retrospective, multicenter, consecutive case series of eight patients with inflammatory ocular neovascularization refractory to standard therapy who were treated with intravitreal bevacizumab and followed for 5 years after first injection. The outcome measures included improvement of best-corrected visual acuity expressed as logarithm of minimum angle of resolution.Results: Mean best-corrected visual acuity significantly improved from 0.58 at baseline (6/23 or 20/76; standard deviation = 0.32) to 0.20 at final assessment (6/10 or 20/32; standard deviation = 0.25) (n = 8; P = 0.02), a gain of 3.8 lines (median: three injections; eight eyes; eight patients). No ocular or systemic complications from intravitreal bevacizumab were noted.Conclusion: At 5 years, intravitreal bevacizumab sustained significant visual improvement in ocular neovascularization due to a variety of inflammatory ocular diseases without major complications after a median of three injections.Keywords: bevacizumab, choroidal neovascularization, punctate inner choroidopathy, toxoplasmosis, uveitis, Vogt–Koyanagi–Harada syndrome
format article
author Mansour AM
Mackensen F
Mahendradas P
Khairallah M
Lai TY
Bashshur Z
author_facet Mansour AM
Mackensen F
Mahendradas P
Khairallah M
Lai TY
Bashshur Z
author_sort Mansour AM
title Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
title_short Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
title_full Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
title_fullStr Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
title_full_unstemmed Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
title_sort five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/ea3ccae7544743858a37bcaf60f0399d
work_keys_str_mv AT mansouram fiveyearvisualresultsofintravitrealbevacizumabinrefractoryinflammatoryocularneovascularization
AT mackensenf fiveyearvisualresultsofintravitrealbevacizumabinrefractoryinflammatoryocularneovascularization
AT mahendradasp fiveyearvisualresultsofintravitrealbevacizumabinrefractoryinflammatoryocularneovascularization
AT khairallahm fiveyearvisualresultsofintravitrealbevacizumabinrefractoryinflammatoryocularneovascularization
AT laity fiveyearvisualresultsofintravitrealbevacizumabinrefractoryinflammatoryocularneovascularization
AT bashshurz fiveyearvisualresultsofintravitrealbevacizumabinrefractoryinflammatoryocularneovascularization
_version_ 1718398397165076480

Ejemplares similares